RMTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RMTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Rockwell Medical's Pre-Tax Income for the three months ended in Dec. 2023 was $-1.51 Mil. Rockwell Medical's Revenue for the three months ended in Dec. 2023 was $22.09 Mil. Therefore, Rockwell Medical's pretax margin for the quarter that ended in Dec. 2023 was -6.84%.
The historical rank and industry rank for Rockwell Medical's Pretax Margin % or its related term are showing as below:
The historical data trend for Rockwell Medical's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Pretax Margin % | Get a 7-Day Free Trial | -55.67 | -49.66 | -52.76 | -25.65 | -10.09 |
Rockwell Medical Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Pretax Margin % | Get a 7-Day Free Trial | -12.23 | -8.90 | -18.28 | -7.88 | -6.84 |
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Pretax Margin % falls into.
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
Rockwell Medical's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Margin | = | Pre-Tax Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -8.439 | / | 83.612 | |
= | -10.09 % |
Rockwell Medical's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
Pretax Margin | = | Pre-Tax Income (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | -1.512 | / | 22.093 | |
= | -6.84 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (NAS:RMTI) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Rockwell Medical's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jesse Neri | officer: SVP, FINANCE | 851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087 |
Joan Lau | director | C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
Russell Skibsted | officer: See Remarks | 15 TRANQUILITY PLACE, LADERA RANCH CA 92694 |
Megan C. Timmins | officer: SVP, General Counsel | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
Mark Strobeck | director, officer: President and CEO | 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087 |
Allen Nissenson | director | 601 HAWAII ST., EL SEGUNDO CA 90245 |
Robert S Radie | director | 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
Andrea Heslin Smiley | director | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
David S. Richmond | 10 percent owner, other: See Footnote 1 | 3568 WILDWOOD AVENUE, JACKSON MI 49202 |
Russell H Ellison | director | 270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025 |
Marc L Hoffman | officer: Chief Medical Officer | 30142 WIXOM ROAD, WIXOM MI 48393 |
John Peter Mclaughlin | director | C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451 |
Richmond Brothers, Inc. | 10 percent owner, other: See Footnote 1 | 7415 FOXWORTH COURT, JACKSON MI 49201 |
Stuart M Paul | director, officer: Chief Executive Officer | HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309 |
Angus W. Smith | officer: Chief Financial Officer | C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960 |
From GuruFocus
By Business Wire Business Wire • 02-28-2023
By Business Wire Business Wire • 11-09-2022
By Business Wire • 01-08-2024
By Business Wire Business Wire • 03-27-2023
By Business Wire Business Wire • 10-17-2022
By Business Wire Business Wire • 05-01-2023
By Business Wire • 10-16-2023
By Business Wire Business Wire • 05-15-2023
By Business Wire Business Wire • 04-17-2023
By Business Wire • 10-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.